Although the safety of the treatment has been previously confirmed [10], the safety and tolerability profile of subcutaneous trastuzumab for patients with HER2-positive BC while under real-world conditions in a context of limited human resources, medicines, and infrastructure, such as Peru [14], remains to be determined. The gene discussed is ERBB2; the disease is breast cancer.